Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833391 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability Study for GSK1838262 (Gabapentin Enacarbil)
A Phase 1 study, sponsored by XenoPort.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00833391 is a Phase 1 study that has completed, run by XenoPort. The registered enrollment target is 16 participants.
The verdict
NCT00833391, a Phase 1 study, has completed, sponsored by XenoPort.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the relative drug concentrations achieved with different formulations of GSK1838262 in healthy volunteers.
Interventions
- DRUG open label
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833391
The ClinicalTrials.gov registry entry for NCT00833391 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is XenoPort, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which open label is the first listed.
NCT00833391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00833391 about?
NCT00833391 is a clinical study titled "Relative Bioavailability Study for GSK1838262 (Gabapentin Enacarbil)". The purpose of this study is to evaluate the relative drug concentrations achieved with different formulations of GSK1838262 in healthy volunteers.
What is the current status of trial NCT00833391?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-01. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00833391?
The interventions under investigation include: open label (DRUG).
Who is sponsoring clinical trial NCT00833391?
This trial is sponsored by XenoPort, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.